25-Feb-2016 - AbbVie Inc.

Major pharma companies sign up to groundbreaking Parkinson's consortium

Seven of the world's largest pharmaceutical companies have signed up to a groundbreaking consortium aimed at accelerating the development of safe and effective therapies for Parkinson's.

The Critical Path for Parkinson's consortium will bring together leading academics; industry members AbbVie, AstraZeneca, Biogen, Eli Lilly and Company, Merck Sharp and Dohme (known as Merck & Co. Inc. in the United States and Canada), Pfizer, and UCB, and founders the Critical Path Institute (C-Path) and Parkinson's UK, to share data, expertise and resources to promote and develop new treatments for Parkinson's.

The consortium, which was launched in October 2015, was formed by Parkinson's UK and C-Path to increase investment into research and development of new Parkinson's treatments.

Dr Arthur Roach, Director of Research at Parkinson's UK, the principal funder of the consortium, says:

"Despite significant advances in our understanding of the genetics, biochemistry and pathology of Parkinson's, the development of new treatments has not kept pace. New treatments are desperately needed to deal with the devastating effects of this progressive condition.

"Investing in clinical trials for brain disorders currently carries a high cost and high risk of failure. As the world's largest patient-led Parkinson's charity, we know that people living with conditions such as Parkinson's have often been disappointed when drugs that showed significant promise early on failed in late stage testing.

"We see the consortium as a crucial part of strategies to develop new treatments that work at the earliest stage of the condition, with the goal of slowing its progression, and eventually finding a cure."

Parkinson's affects 127,000 people in the United Kingdom, and approximately 7 million people worldwide. In 2012/13, the National Health Service (NHS) spent more than £212 million on caring for people with Parkinson's in England (1), with the cost of the condition in the United States approximately US$25 billion per year (2). With the baby boomer generation becoming older, the number of people with neurodegenerative conditions, including Parkinson's, is likely to increase and will become one of the biggest issues faced by healthcare.

The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) estimated that the cost of developing a single drug was US$1.3 billion, rising from US$138 million in 1978 (3), a tenfold increase attributed to a multiplicity of factors faced by drug research.

Diane Stephenson, PhD, Executive Director, Critical Path for Parkinson's consortium, C- Path, says:

"With the increase in the costs of getting a drug to market, the design of a clinical trial is a crucial part of a drug's success. There is a strong realisation from the industry that collaboration among industry, academia, and worldwide regulatory agencies, along with the sharing of data, has the potential to create a more efficient development process. This recognition is evidenced by the fast pace at which members of this new consortium have joined."

Parkinson's UK has committed over £1million to the Critical Path for Parkinson's consortium.

Facts, background information, dossiers
  • AstraZeneca
  • BioGene
  • Eli Lilly
  • MSD
  • Pfizer
  • UCB
More about AbbVie
More about AstraZeneca
More about BioGene
  • Companies

    BioGene Ltd

    We aim to provide a 'solution-based' portfolio of products, services and support - to encompass the key applicational areas of molecular biology to include Nucleic Acid Purification, Target Amplification and Post-Amplification Analyses. more

More about Eli Lilly
More about Merck Sharp & Dohme
  • News

    Curve Therapeutics Announces Collaboration with MSD for Next Generation Drug Discovery Platform

    Curve Therapeutics, a private biotechnology startup pioneering a potentially game-changing, functional drug discovery platform, announces a global research collaboration with MSD, the trade name of Merck & Co., Inc., Kenilworth, NJ USA, to discover and validate modulators of up to five ther ... more

    Merck Discontinues Development of SARS-CoV-2/COVID-19 Vaccine Candidates

    Merck, known as MSD outside the United States and Canada, announced that the company is discontinuing development of its SARS-CoV-2/COVID-19 vaccine candidates, V590 and V591, and plans to focus its SARS-CoV-2/COVID-19 research strategy and production capabilities on advancing two therapeut ... more

    Seattle Genetics and Merck & Co Announce Two Strategic Oncology Collaborations

    Seattle Genetics, Inc. and Merck, known as MSD outside the United States and Canada, announced two new strategic oncology collaborations. The companies will globally develop and commercialize Seattle Genetics’ ladiratuzumab vedotin, an investigational antibody-drug conjugate (ADC) targeting ... more

  • Companies

    Merck Sharp & Dohme Limited

    We are inspired by the difference we can make in the lives of people around the world through the innovative medicines, vaccines, and consumer health and animal products we discover and produce. Our products cover a broad range of areas, including heart and respiratory health, infectious di ... more

    Merck & Co., Inc.

    Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The company devotes extensive efforts to increase access ... more

    Merck & Co., Inc.

    This site is intended for residents of the United States and Canada and their territories only. Merck is a leading global biopharmaceutical company that has been inventing for life for more than a century, bringing forward medicines and vaccines for many of the world's most challenging dise ... more

More about Pfizer
More about UCB
  • News

    Evotec and UCB sign multi-year CNS pharmacology agreement

    Evotec AG announced a collaboration with UCB to provide a broad range of in vitro pharmacology services. Under the terms of the three-year agreement, Evotec will support UCB's in vitro pharmacology team in drug discovery projects across multiple target classes, particularly in the CNS space ... more

    UCB and Baylor College of Medicine launch strategic alliance in neurodegeneration

    UCB and Baylor College of Medicine announced that they have started a strategic research alliance, led at Baylor by Professor Huda Zoghbi, that aims to discover new therapeutics to treat neurodegenerative disease. This research alliance reflects UCB’s strategy to accelerate discovery and de ... more

    UCB announces Phase 3 clinical trial program for epratuzumab in Systemic Lupus Erythematosus did not meet primary endpoint

    UCB announced that the two EMBODY™ Phase 3 clinical studies for epratuzumab in Systemic Lupus Erythematosus (SLE) did not meet their primary clinical efficacy endpoints in either dose in both studies. Treatment response in patients who received epratuzumab in addition to standard therapy wa ... more

  • Companies

    UCB Pharma S.A.

    With a unique combination of expertise in biology and chemistry, UCB is a global biopharma focusing on severe diseases in three therapeutic areas - CNS, inflammation and oncology. more

    UCB GmbH

    UCB, Brussels, Belgium is a global leader in the biopharmaceutical industry dedicated to the research, development and commercialization of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflam ... more

    UCB de Mexico S.A. de C.V.

    UCB, Brussels, Belgium is a global leader in the biopharmaceutical industry dedicated to the research, development and commercialization of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflam ... more